| P/E (FY) | — | Sales (TTM) | — |
| Earnings (TTM) | — | ROE | — |
| Net Margin | — | ROIC | — |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | — |
| Market Cap | $1.22B | Trading Days | 50 |
| 52W High | 33.32 |
| 52W Low | 24.90 |
| % Off High | −17.11% |
| Ann. Volatility (1Y) | 70.73% | Ann. Volatility (3Y) | 70.73% |
| Sharpe (1Y) | −0.13 | Sharpe (3Y) | −0.13 |
| Max Drawdown (1Y) | −22.11% | Max Drawdown (3Y) | −22.11% |
| YTD | −6.34% | Since inception | −6.34% |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| OPK | OPKO HEALTH, INC. | $1.23B | — |
| ORIC | Oric Pharmaceuticals, Inc. | $1.23B | — |
| MNKD | MANNKIND CORP | $1.21B | 195.5 |
| ARDX | ARDELYX, INC. | $1.26B | — |
| ETON | Eton Pharmaceuticals, Inc. | $1.28B | — |
| COLL | COLLEGIUM PHARMACEUTICAL, INC | $1.16B | 20.8 |
| WVE | Wave Life Sciences Ltd. | $1.13B | — |
| SDGR | Schrodinger, Inc. | $1.12B | — |
| CRVS | Corvus Pharmaceuticals, Inc. | $1.12B | — |
| SPTX | Seaport Therapeutics, Inc. | $1.10B | — |
| SVRA | Savara Inc | $1.09B | — |
| MLTX |
| MoonLake Immunotherapeutics |
| $1.38B |
| — |
